Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Abstract Purpose A hallmark of acute respiratory distress syndrome (ARDS) is hypoxaemic respiratory failure due to pulmonary vascular hyperpermeability. The tyrosine kinase inhibitor imatinib reversed pulmonary capillary leak in preclinical studies and improved clinical outcomes in hospitalized COVI...

Full description

Bibliographic Details
Main Authors: Leila N. Atmowihardjo, Job R. Schippers, Erik Duijvelaar, Imke H. Bartelink, Pierre M. Bet, Noortje E. L. Swart, Nienke van Rein, Keith Purdy, David Cavalla, Andrew McElroy, Sarah Fritchley, Anton Vonk Noordegraaf, Henrik Endeman, Patricia van Velzen, Matty Koopmans, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus J. Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Critical Care
Subjects:
COVID-19
ARDS
Imatinib
Vascular permeability
Endothelial barrier dysfunction
Pulmonary edema
Online Access:https://doi.org/10.1186/s13054-023-04516-4

Internet

https://doi.org/10.1186/s13054-023-04516-4

Similar Items